pegyl
antivir
immunoregulatori
drug
serv
foundat
treatment
hepat
c
viru
hcv
infect
two
decad
current
two
pegifn
market
combin
broadspectrum
antivir
ribavirin
rbv
treatment
chronic
hcv
two
drug
differenti
size
natur
coval
attach
polyethylen
glycol
peg
moieti
although
exhibit
differ
pharmacokinet
dose
regimen
consensu
two
drug
clinic
equival
hcv
infect
affect
million
peopl
worldwid
lead
caus
cirrhosi
hepatocellular
carcinoma
although
preval
hcv
appear
decreas
develop
nation
mortal
due
liver
diseas
secondari
hcv
infect
expect
continu
rise
next
year
although
minor
patient
acut
hcv
infect
abl
clear
viru
spontan
patient
develop
chronic
hcv
infect
defin
detect
hcv
rna
longer
month
chronic
infect
establish
rare
resolv
spontan
primari
goal
treatment
achiev
sustain
virolog
respons
svr
character
undetect
serum
viral
rna
week
end
therapi
consid
clinic
cure
infect
associ
lower
morbid
mortal
hcv
divid
seven
recogn
genotyp
differ
nucleotid
site
hcv
genotyp
differenti
distribut
global
genotyp
preval
north
america
south
america
europ
hcv
genotyp
highli
associ
respons
combin
either
firstgener
proteas
inhibitor
daa
boceprevir
boc
telaprevir
tvr
tripl
therapi
demonstr
svr
rate
secondgener
proteas
inhibitor
simeprevir
approv
food
drug
administr
fda
rais
svr
rate
sofosbuvir
recent
approv
fda
shown
great
potenti
improv
svr
rate
even
either
part
tripl
therapi
combin
part
ifnfre
therapi
either
simeprevir
ledipasvir
final
trial
recent
fdaapprov
ifnfre
regim
consist
paritaprevir
boost
ritonavir
ombitasvir
dasabuvir
ribavirin
demonstr
svr
rate
greater
treatmentna
patient
previou
nonrespond
hcv
genotyp
cirrhosi
result
american
associ
studi
liver
diseas
recent
revis
practic
guidelin
hcv
genotyp
patient
includ
ifnfre
regim
boast
improv
toler
well
efficaci
attach
peg
moieti
pegyl
major
advanc
led
improv
pharmacokinet
ifn
compar
administr
unmodifi
three
time
week
pegifn
allow
onceweekli
dose
administr
avoid
larg
fluctuat
serum
concentr
branch
kda
peg
chain
coval
attach
lysin
residu
circul
intact
molecul
wherea
linear
kda
peg
chain
coval
attach
unstabl
urethan
bond
hydrolyz
inject
size
natur
peg
moieti
attach
caus
differ
pharmacokinet
dose
regimen
drug
absorpt
halflif
unmodifi
h
wherea
h
respect
addit
longer
halflif
highli
local
smaller
volum
distribut
l
kg
highest
concentr
occur
liver
patient
administ
singl
dose
reach
mean
maximum
serum
concentr
mean
time
h
administr
follow
multipl
dose
weekli
mean
maximum
serum
concentr
reach
mean
time
h
contrast
maximum
serum
concentr
achiev
h
administr
sustain
h
smaller
peaktotrough
ratio
compar
ratio
greater
multipl
dose
thu
exhibit
less
fluctuat
serum
concentr
dose
interv
longer
halflif
limit
distribut
allow
fix
weekli
dose
convers
weekli
dosag
must
adjust
accord
bodi
weight
rel
short
serum
halflif
pegifn
signific
number
patient
may
undetect
level
drug
end
weekli
dose
interv
may
caus
viral
rebound
suggest
shorter
dosag
interv
twiceweekli
regimen
may
necessari
although
yet
formal
test
clear
liver
kidney
clear
kidney
rest
clear
liver
degrad
interact
cellular
ifn
receptor
compar
standard
significantli
reduc
renal
clearanc
rbv
coadministr
affect
pharmacokinet
pegifn
pegifn
affect
rbv
patient
administ
combin
therapi
mean
peak
plasma
rbv
concentr
week
ngml
daili
rbv
dose
mg
respect
week
dose
regimen
produc
mean
peak
plasma
rbv
concentr
ngml
respect
account
fivefold
rbv
accumul
regardless
dose
group
appar
clearanc
rbv
consist
lh
act
directli
indirectli
antivir
although
exact
mechan
inhibit
hcv
replic
still
well
understood
exert
effect
induc
nonvirusspecif
immun
respons
cell
upregul
mani
ifnstimul
gene
isg
encod
antivir
effector
protein
shown
fig
hcv
rna
detect
host
innat
immun
system
recogn
sever
pathogen
recognit
receptor
retino
acid
induc
encod
gene
retino
acid
induc
activ
adapt
mitochondri
antivir
signal
protein
induc
phosphoryl
ifn
regulatori
factor
two
protein
heterodimer
transloc
nucleu
induc
express
secret
variou
ifn
includ
circul
bind
two
uniqu
cell
surfac
receptor
subunit
bound
heterodim
form
activ
janusactiv
kinas
jak
tyrosin
kinas
turn
phosphoryl
cytoplasm
signal
transduc
activ
transcript
stat
protein
phosphoryl
dimer
bind
form
interferonstimul
gene
factor
complex
transloc
nucleu
bind
interferonstimul
respons
element
upon
bind
dna
induc
transcript
isg
mrna
encod
number
effector
protein
microarray
analys
shown
induc
hundr
isg
mani
relat
antivir
activ
other
involv
lipid
metabol
apoptosi
protein
degrad
inflammatori
respons
among
major
isg
believ
play
import
role
inhibit
hcv
replic
oligoadenyl
synthetas
eukaryot
translat
initi
factor
kinas
formerli
known
pkr
adenosin
deaminas
rnaspecif
mx
dynaminlik
gtpase
convers
antivir
signal
control
antiinflammatori
isg
ubiquitinspecif
peptidas
suppressor
cytokin
signal
protein
inhibitor
activ
act
part
neg
feedback
loop
restrict
extent
durat
ifn
respons
direct
indirect
inhibit
stat
signal
addit
antivir
activ
exert
immunolog
effect
interact
adapt
innat
immun
respons
promot
memori
tcell
prolifer
prevent
tcell
apoptosi
stimul
naturalkil
cell
activ
dendriticcel
matur
final
shown
increas
product
major
histocompat
complex
class
class
ii
molecul
howev
immunolog
properti
like
directli
involv
hcv
clearanc
ifnbas
therapi
thought
exert
effect
primarili
antivir
activ
virolog
declin
often
refer
viral
kinet
respons
import
ontreat
predictor
achiev
svr
therapi
rapid
virolog
clearanc
rvr
earli
virolog
respons
evr
defin
undetect
hcv
rna
week
log
declin
hcv
rna
week
respect
shown
associ
svr
inde
svr
rate
patient
achiev
rvr
greater
treatment
regim
shorten
patient
pharmacodynam
appear
similar
pharmacodynam
comparison
shown
two
form
similar
biolog
activ
evidenc
induct
pattern
synthetas
neopterin
major
histocompat
complex
class
molecul
microglobulin
howev
one
studi
found
exhibit
greater
activ
isg
group
patient
hcv
genotyp
infect
similar
activ
jakstat
pathway
upregul
number
isg
bind
ifnstimul
respons
element
establish
antivir
state
cell
shown
experiment
model
inhibit
hcv
replic
coadminist
antivir
effect
addit
although
increas
express
similar
set
isg
downstream
pathway
exert
effect
signal
uniqu
receptor
bind
receptor
complex
highli
express
hepatocyt
kinet
respons
differ
two
ifn
exhibit
rapid
phosphoryl
stat
yet
delay
prolong
express
variou
isg
compar
limit
distribut
receptor
among
factor
suggest
pegyl
form
may
better
toler
mechan
action
rbv
hcv
remain
unclear
suggest
rbv
act
directli
inhibit
hcv
replic
inhibit
host
enzym
inosin
monophosph
dehydrogenas
convers
rbv
may
act
indirectli
hcv
viral
replic
caus
rapid
lethal
mutat
virion
deplet
intracellular
guanosin
triphosph
requir
viral
rna
synthesi
final
suggest
rbv
may
exert
effect
immunomodulatori
activ
mark
variat
hcv
clearanc
respons
among
differ
ethnic
group
among
patient
infect
hcv
genotyp
long
point
host
genet
factor
determin
treatment
success
sever
genomewid
associ
studi
independ
show
sever
snp
chromosom
near
strongli
associ
respons
therapi
individu
infect
hcv
genotyp
studi
demonstr
hcv
genotyp
patient
favor
variant
locu
cc
tt
two
three
time
like
achiev
svr
combin
therapi
also
higher
rate
spontan
hcv
clearanc
absenc
treatment
compar
patient
unfavor
c
genotyp
respect
find
later
valid
sever
candid
gene
studi
associ
genotyp
svr
confirm
independ
studi
variou
popul
asia
europ
latin
america
thu
variat
constitut
strongest
pretreat
indic
respons
hcv
genotyp
patient
even
account
known
clinic
predict
factor
therapi
initi
favor
cc
genotyp
also
associ
significantli
higher
rate
viral
clearanc
treatment
point
indic
better
viral
kinet
well
increas
rate
rvr
evr
endoftreat
respons
reduc
virolog
relaps
rate
studi
patient
infect
hcv
genotyp
found
rel
weak
correl
genotyp
treatment
respons
mani
fail
achiev
statist
signific
like
svr
rate
gener
high
among
hcv
genotyp
patient
variat
svr
rate
among
differ
genotyp
gener
smaller
patient
infect
hcv
genotyp
genotyp
may
littl
valu
predict
svr
howev
signific
associ
genotyp
rvr
demonstr
studi
hcv
genotyp
patient
genotyp
may
use
predict
rvr
patient
hcv
genotyp
inform
decis
shorten
treatment
durat
minim
treatmentassoci
advers
effect
coinfect
hcv
rel
common
among
patient
hiv
infect
like
common
rout
transmiss
progress
hcvrelat
liver
diseas
acceler
coinfect
patient
hcv
becom
import
caus
morbid
mortal
among
hivinfect
individu
unfortun
hivhcvcoinfect
patient
also
less
like
respond
therapi
compar
hcv
monoinfect
patient
thu
predictor
respons
treatment
use
identifi
best
candid
current
therapi
associ
genotyp
therapi
outcom
consist
demonstr
across
studi
subgroup
analys
hiv
patient
coinfect
hcv
genotyp
patient
hcv
genotyp
sever
studi
shown
associ
favor
genotyp
cc
tt
higher
svr
rate
although
one
studi
compar
two
snp
found
better
predictor
respons
genotyp
may
also
use
patient
coinfect
hiv
hcv
genotyp
undergon
previous
fail
therapi
identifi
nonrespond
would
like
benefit
retreat
addit
genotyp
demonstr
import
predictor
reinfect
hcv
patient
undergo
liver
transplant
sever
independ
cohort
favor
cc
tt
genotyp
donor
recipi
shown
associ
higher
svr
rate
howev
studi
identifi
correl
perform
hcv
genotyp
patient
littl
evid
associ
among
genotyp
favor
polymorph
differenti
distribut
among
ethnic
group
africanamerican
lowest
frequenc
allel
frequenc
eastern
southeastern
asian
highest
frequenc
near
caucasian
hispan
intermedi
frequenc
respect
snp
exhibit
strong
linkag
disequilibrium
except
patient
african
ancestri
partial
linkag
disequilibrium
caucasian
nearcomplet
linkag
disequilibrium
asian
vari
frequenc
favor
allel
help
explain
differ
svr
rate
among
differ
ethnic
popul
exampl
estim
approxim
half
differ
svr
rate
among
europeanamerican
africanamerican
due
c
allel
still
africanamerican
patient
favor
cc
genotyp
viral
kinet
shown
slower
svr
rate
lower
europeanamerican
genotyp
may
suggest
ethnic
remain
independ
predictor
outcom
point
exist
current
unknown
gene
variant
influenc
treatment
respons
particularli
africanamerican
biolog
implic
variat
actual
mechan
genotyp
affect
respons
rbv
remain
unclear
although
effect
polymorph
product
intrahepat
isg
express
still
controversi
suggest
isg
express
pattern
may
part
explain
differ
svr
rate
interestingli
patient
unfavor
genotyp
cttt
found
higher
intrahepat
isg
express
baselin
associ
failur
respond
treatment
one
explan
patient
unfavor
genotyp
exhibit
continu
ineffectu
intrahepat
express
isg
time
ifnsign
inhibitor
protein
inhibitor
activ
stat
also
upregul
preactiv
isg
respons
may
insuffici
clear
viru
may
caus
reduc
sensit
therapi
neg
regul
jakstat
signal
ifnsign
inhibitor
thu
even
administ
cell
may
fail
induc
strong
enough
isg
express
unabl
clear
viru
convers
patient
favor
genotyp
may
induc
weaker
respons
hcv
rna
thu
less
ifn
express
occur
result
lower
isg
level
baselin
higher
viral
load
administ
may
less
inhibit
ifn
signal
neg
regulatori
molecul
caus
cell
sensit
ifn
stronger
isg
induct
possibl
ultim
unrestrain
ifn
signal
transduct
strong
isg
stimul
may
result
effect
clearanc
viru
inde
patient
favor
genotyp
observ
elimin
hcv
effici
time
point
treatment
indic
better
viral
kinet
yet
despit
known
associ
treatment
respons
propos
mechan
effect
remain
unknown
whether
favor
snp
actual
exert
biolog
effect
simpli
linkag
disequilibrium
function
polymorph
recent
studi
genet
region
upstream
uncov
new
transient
induc
region
encompass
dinucleotid
variant
origin
design
high
linkag
disequilibrium
suggest
possibl
causal
variant
frameshift
variant
creat
novel
gene
encod
protein
similar
ident
like
exist
three
member
famili
exhibit
antivir
activ
vitro
bind
receptor
complex
activ
jakstat
pathway
patient
allel
express
full
protein
wherea
tt
allel
caus
frame
shift
lead
abrog
protein
interestingli
tt
allel
strongli
associ
spontan
treatmentinduc
svr
indic
disrupt
favor
appar
associ
product
reduc
likelihood
spontan
therapyinduc
clearanc
hcv
suggest
novel
ifn
may
respons
observ
clinic
phenotyp
although
mechan
remain
unclear
contrast
ifn
protein
poorli
secret
hypothes
may
impair
hcv
clearanc
block
bind
receptor
note
shown
peripher
blood
mononuclear
cell
involv
stimul
protein
mrna
high
plasma
level
associ
treatment
failur
strongli
correl
novel
variant
provid
addit
inform
predict
treatment
respons
caucasian
patient
convers
moder
correl
caucasian
patient
suggest
may
serv
better
predictor
treatment
outcom
likewis
genotyp
may
better
predictor
treatment
respons
patient
african
ancestri
show
weak
correl
moder
correl
popul
taken
togeth
identif
character
function
variant
repres
new
step
toward
elucid
genet
mechan
hcv
clearanc
role
ifn
polymorph
predict
hcv
treatment
respons
incorpor
daa
hcv
treatment
arsen
question
emerg
whether
genotyp
remain
relev
predict
treatment
outcom
tripleact
therapi
includ
new
agent
initi
data
suggest
genotyp
may
remain
use
less
tradit
dual
therapi
date
wellstudi
tripl
therapi
combin
rbv
firstgener
proteas
inhibitor
boc
tvr
treatmentna
patient
svr
rate
patient
treat
tripl
therapi
includ
boc
tvr
respect
significantli
higher
favor
cc
genotyp
compar
ct
tt
genotyp
patient
exhibit
better
viral
kinet
respons
lower
risk
select
resistanceassoci
hcv
variant
patient
previous
treat
therapi
genotyp
significantli
associ
svr
relaps
partial
respond
previou
null
respond
favor
cc
genotyp
exhibit
higher
svr
rate
compar
unfavor
genotyp
regard
secondgener
proteas
inhibitor
effect
genotyp
treatment
respons
shown
weaker
expect
remain
use
predict
respons
especi
treatmentna
patient
exampl
genotyp
shown
significantli
associ
svr
week
treatmentna
treatmentexperienc
hcv
genotyp
patient
undergo
tripl
therapi
proteas
inhibitor
simeprevir
similarli
identifi
independ
pretreat
predictor
svr
treatmentna
patient
hcv
genotyp
treat
polymeras
inhibitor
sofosbuvir
combin
also
suggest
stratif
patient
accord
genotyp
ongo
clinic
trial
new
treatment
use
individu
futur
tripl
therapi
optim
outcom
final
appear
margin
affect
treatment
respons
newli
develop
ifnfre
therapi
although
genotyp
may
relev
predict
svr
demonstr
variat
associ
viral
kinet
ifnfre
treatment
howev
studi
larger
cohort
need
confirm
associ
apart
wellestablish
associ
describ
numer
studi
demonstr
polymorph
gene
may
associ
treatment
respons
advers
reaction
therapi
one
signific
drugrel
toxic
combin
therapi
rbvinduc
hemolyt
anemia
caus
patient
reduc
rbv
dose
discontinu
treatment
genomewid
associ
studi
identifi
polymorph
itpa
gene
encod
inosin
triphosph
pyrophosphohydrolas
itpa
shown
protect
ribavirininduc
hemolyt
anemia
hcv
genotyp
patient
treat
subsequ
analysi
identifi
snp
two
function
variant
carri
c
allel
also
protect
rbvinduc
anemia
europeanamerican
hcv
genotyp
popul
result
replic
japanes
popul
extend
hcv
genotyp
well
patient
treat
plu
tvr
tripl
therapi
although
variant
establish
associ
itpa
defici
mechan
condit
protect
rbvinduc
anemia
remain
unclear
genet
variant
ldlr
gene
encod
lowdens
lipoproteincholesterol
receptor
shown
predict
svr
chronic
hcv
patient
treat
therapi
ldlr
variant
appear
addit
effect
predict
svr
thu
consider
ldlr
accur
predict
svr
use
either
genotyp
singli
final
shown
vitamin
defici
associ
nonrespons
combin
therapi
suggest
variant
vitamin
receptor
gene
vdr
may
play
role
treatment
outcom
recent
demonstr
common
nonsynonym
snp
vdr
gene
predict
treatment
respons
therapi
hcv
genotyp
patient
minor
tallel
carrier
increas
likelihood
achiev
svr
treatment
hcv
genotyp
infect
made
remark
progress
last
two
decad
allow
svr
rate
climb
new
high
chronic
infect
tradit
difficult
cure
treatmentna
patient
increas
svr
possibl
addit
daa
combin
therapi
pharmacogenet
offer
anoth
use
tool
optim
individu
treatment
regimen
allow
clinician
make
inform
decis
treatment
option
modifi
dose
decid
durat
treatment
regimen
avoid
certain
advers
reaction
associ
therapi
particular
genotyp
establish
robust
predictor
treatment
outcom
therapi
era
new
daa
variat
may
remain
use
although
effect
attenu
howev
newer
therapi
extrem
expens
thu
regimen
like
remain
mainstay
hcv
treatment
develop
nation
develop
nation
like
usa
adopt
newer
effect
treatment
studi
need
confirm
initi
associ
found
genotyp
treatment
respons
although
like
theori
suggest
still
certain
genotyp
affect
treatment
outcom
research
need
elucid
exact
mechan
improv
mechanist
understand
genet
determin
svr
help
identifi
novel
biomark
spontan
clearanc
determin
new
target
person
treatment
hcv
infect
ultim
allow
improv
treatment
respons
rate
svr
rate
climb
new
high
greater
advent
ifnfre
regimen
replac
ifnbas
therapi
develop
nation
futur
genotyp
hcv
treatment
bright
inde
styliz
depict
pharmacodynam
hepatocyt
fulli
interact
version
avail
pharmgkb
http
wwwpharmgkborgpathway
